+

WO2005067901A3 - Methodes permettant de traiter et de prevenir l'hypertension et les troubles associes a l'hypertension - Google Patents

Methodes permettant de traiter et de prevenir l'hypertension et les troubles associes a l'hypertension Download PDF

Info

Publication number
WO2005067901A3
WO2005067901A3 PCT/US2005/000677 US2005000677W WO2005067901A3 WO 2005067901 A3 WO2005067901 A3 WO 2005067901A3 US 2005000677 W US2005000677 W US 2005000677W WO 2005067901 A3 WO2005067901 A3 WO 2005067901A3
Authority
WO
WIPO (PCT)
Prior art keywords
hypertension
treating
methods
related disorders
preventing
Prior art date
Application number
PCT/US2005/000677
Other languages
English (en)
Other versions
WO2005067901A2 (fr
Inventor
Stephanie W Watts
Carrie A Northcott
Original Assignee
Univ Michigan State
Stephanie W Watts
Carrie A Northcott
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan State, Stephanie W Watts, Carrie A Northcott filed Critical Univ Michigan State
Priority to CA002552664A priority Critical patent/CA2552664A1/fr
Publication of WO2005067901A2 publication Critical patent/WO2005067901A2/fr
Publication of WO2005067901A3 publication Critical patent/WO2005067901A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des méthodes permettant de traiter l'hypertension ainsi que des affections associées à l'hypertension au moyen de composés inhibant sélectivement l'activité de PI-3-K p110δ.
PCT/US2005/000677 2004-01-08 2005-01-07 Methodes permettant de traiter et de prevenir l'hypertension et les troubles associes a l'hypertension WO2005067901A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002552664A CA2552664A1 (fr) 2004-01-08 2005-01-07 Methodes permettant de traiter et de prevenir l'hypertension et les troubles associes a l'hypertension

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US53541204P 2004-01-08 2004-01-08
US60/535,412 2004-01-08
US54710704P 2004-02-24 2004-02-24
US60/547,107 2004-02-24
US54862004P 2004-02-27 2004-02-27
US60/548,620 2004-02-27

Publications (2)

Publication Number Publication Date
WO2005067901A2 WO2005067901A2 (fr) 2005-07-28
WO2005067901A3 true WO2005067901A3 (fr) 2005-12-01

Family

ID=34799611

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/000677 WO2005067901A2 (fr) 2004-01-08 2005-01-07 Methodes permettant de traiter et de prevenir l'hypertension et les troubles associes a l'hypertension

Country Status (3)

Country Link
US (1) US20050239809A1 (fr)
CA (1) CA2552664A1 (fr)
WO (1) WO2005067901A2 (fr)

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8440677B2 (en) 2009-03-24 2013-05-14 Gilead Calistoga Llc Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
US8546409B2 (en) 2009-04-20 2013-10-01 Gilead Calistoga Llc Methods of treatment for solid tumors
US8569323B2 (en) 2009-07-15 2013-10-29 Intellikine, Llc Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof
USRE44599E1 (en) 2004-05-13 2013-11-12 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
US8604032B2 (en) 2010-05-21 2013-12-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
US8642604B2 (en) 2006-04-04 2014-02-04 The Regents Of The University Of California Substituted pyrazolo[3,2-d]pyrimidines as anti-cancer agents
US8691829B2 (en) 2009-07-21 2014-04-08 Gilead Calistoga Llc Treatment of liver disorders with PI3K inhibitors
US8697709B2 (en) 2008-10-16 2014-04-15 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8703777B2 (en) 2008-01-04 2014-04-22 Intellikine Llc Certain chemical entities, compositions and methods
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
US8785470B2 (en) 2011-08-29 2014-07-22 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8785454B2 (en) 2009-05-07 2014-07-22 Intellikine Llc Heterocyclic compounds and uses thereof
US8809349B2 (en) 2011-01-10 2014-08-19 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US8865730B2 (en) 2012-03-05 2014-10-21 Gilead Calistoga Llc Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
US8901133B2 (en) 2010-11-10 2014-12-02 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9096611B2 (en) 2008-07-08 2015-08-04 Intellikine Llc Kinase inhibitors and methods of use
US9238070B2 (en) 2008-11-13 2016-01-19 Gilead Calistoga Llc Therapies for hematologic malignancies
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
US9321772B2 (en) 2011-09-02 2016-04-26 The Regents Of The University Of California Substituted pyrazolo[3,4-D]pyrimidines and uses thereof
US9359365B2 (en) 2013-10-04 2016-06-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9359349B2 (en) 2007-10-04 2016-06-07 Intellikine Llc Substituted quinazolines as kinase inhibitors
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9487772B2 (en) 2000-04-25 2016-11-08 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
US10131668B2 (en) 2012-09-26 2018-11-20 The Regents Of The University Of California Substituted imidazo[1,5-a]pYRAZINES for modulation of IRE1
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016348A1 (fr) * 2003-08-14 2005-02-24 Icos Corporation Methodes d'inhibition de reponses immunes stimulees par un facteur endogene
CA2563038C (fr) 2004-04-02 2013-10-29 Gaik Beng Kok Composes neurologiquement actifs
CA2730540A1 (fr) * 2004-05-13 2005-12-01 Vanderbilt University Inhibiteurs selectifs de la phosphoinositide-3-kinase delta pour inhiber l'angiogenese
CA2598409A1 (fr) * 2005-02-17 2006-08-24 Icos Corporation Procede d'inhibition d'accumulation de leucocytes
BRPI0609509A2 (pt) 2005-03-30 2010-04-13 Conforma Therapeutics Corp composto ou um polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso do composto, polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável
EP2079739A2 (fr) 2006-10-04 2009-07-22 Pfizer Products Inc. Dérivés de pyrido[4,3-d]pyrimidin-4(3h)-one utilisés en tant qu'antagonistes du récepteur calcique
EA024359B1 (ru) 2007-06-29 2016-09-30 Джилид Сайэнс, Инк. Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
WO2010006072A2 (fr) 2008-07-08 2010-01-14 The Regents Of The University Of California Modulateurs de mtor et leurs utilisations
US20110294803A1 (en) * 2008-12-04 2011-12-01 Law Amanda J Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders
KR101687841B1 (ko) 2008-12-09 2016-12-19 길리애드 사이언시즈, 인코포레이티드 톨-유사 수용체의 조절제
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
EA020488B1 (ru) 2009-10-22 2014-11-28 Джилид Сайэнс, Инк. Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
CA2864643A1 (fr) 2012-03-13 2013-09-19 Respivert Limited Nouvelles formulations pharmaceutiques
JP6584952B2 (ja) 2012-11-01 2019-10-02 インフィニティー ファーマシューティカルズ， インコーポレイテッド Ｐｉ３キナーゼアイソフォームモジュレーターを用いる癌の治療
TW201522341A (zh) 2013-03-15 2015-06-16 Respivert Ltd 化合物
US9227977B2 (en) 2013-03-15 2016-01-05 Respivert Ltd. Phosphoinositide 3-kinase inhibitors
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
WO2015051241A1 (fr) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Composés hétérocycliques et leurs utilisations
EP3083623A1 (fr) 2013-12-20 2016-10-26 Gilead Calistoga LLC Formes polymorphes d'un sel chlorhydrate de la (s)-2-(9h-purine-6-ylamino)propyl)-5-fluoro-3-phénylquinazolin-4(3h)-one
WO2015095601A1 (fr) 2013-12-20 2015-06-25 Gilead Calistoga Llc Procédés de synthèse d'inhibiteurs de la phosphatidylinositol 3-kinase
SG10201808053XA (en) 2014-03-19 2018-10-30 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
JP6455995B2 (ja) 2014-06-13 2019-01-23 ギリアード サイエンシーズ， インコーポレイテッド ホスファチジルイノシトール３−キナーゼ阻害剤
KR20170082490A (ko) 2014-07-04 2017-07-14 루핀 리미티드 Pi3k 억제제로서 퀴놀리지논 유도체
CN106714800B (zh) 2014-07-11 2021-09-03 吉利德科学公司 用于治疗hiv的toll样受体调节剂
KR20170054481A (ko) 2014-09-16 2017-05-17 길리애드 사이언시즈, 인코포레이티드 톨-유사 수용체 조정제의 고체 형태
EP3317277B1 (fr) 2015-07-01 2021-01-20 Crinetics Pharmaceuticals, Inc. Modulateurs de la somatostatine et leurs utilisations
MX2021001186A (es) 2015-11-20 2022-10-11 Forma Therapeutics Inc Purinonas como inhibidores de proteasa especifica de ubiquitina 1.
WO2017161116A1 (fr) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues de composés isoquinolinone et quinazolinone et leurs utilisations comme inhibiteurs de la kinase pi3k
WO2017214269A1 (fr) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Composés hétérocycliques et leurs utilisations
KR20190033526A (ko) 2016-06-24 2019-03-29 인피니티 파마슈티칼스, 인코포레이티드 병용 요법
US11028068B2 (en) 2017-07-25 2021-06-08 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001081346A2 (fr) * 2000-04-25 2001-11-01 Icos Corporation Inhibiteurs de la phosphatidyl-inositol 3-kinase delta humaine
WO2003035075A1 (fr) * 2001-10-19 2003-05-01 Icos Corporation Inhibiteurs de phosphatidyl-inositol 3-kinase delta
WO2005016349A1 (fr) * 2003-08-14 2005-02-24 Icos Corporation Methodes d'inhibition de l'accumulation des leucocytes
WO2005016348A1 (fr) * 2003-08-14 2005-02-24 Icos Corporation Methodes d'inhibition de reponses immunes stimulees par un facteur endogene
WO2005042519A1 (fr) * 2003-10-31 2005-05-12 Warner-Lambert Company Llc Pyrimidines a titre d'inhibiteurs de phosphoinositide-3-kinases (pi3k)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869040A (en) * 1995-06-07 1999-02-09 Biogen, Inc Gene therapy methods and compositions
US5858753A (en) * 1996-11-25 1999-01-12 Icos Corporation Lipid kinase

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001081346A2 (fr) * 2000-04-25 2001-11-01 Icos Corporation Inhibiteurs de la phosphatidyl-inositol 3-kinase delta humaine
WO2003035075A1 (fr) * 2001-10-19 2003-05-01 Icos Corporation Inhibiteurs de phosphatidyl-inositol 3-kinase delta
WO2005016349A1 (fr) * 2003-08-14 2005-02-24 Icos Corporation Methodes d'inhibition de l'accumulation des leucocytes
WO2005016348A1 (fr) * 2003-08-14 2005-02-24 Icos Corporation Methodes d'inhibition de reponses immunes stimulees par un facteur endogene
WO2005042519A1 (fr) * 2003-10-31 2005-05-12 Warner-Lambert Company Llc Pyrimidines a titre d'inhibiteurs de phosphoinositide-3-kinases (pi3k)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DREES B E ET AL: "Therapeutic potential of phosphoinositide 3-kinase inhibitors", EXPERT OPINION ON THERAPEUTIC PATENTS 2004 UNITED KINGDOM, vol. 14, no. 5, 2004, pages 703 - 732, XP002346345, ISSN: 1354-3776 *
NORTHCOTT CARRIE A ET AL: "PI3-kinase upregulation and involvement in spontaneous tone in arteries from DOCA-salt rats: is p110delta the culprit?", HYPERTENSION. APR 2004, vol. 43, no. 4, April 2004 (2004-04-01), pages 885 - 890, XP002346346, ISSN: 1524-4563 *
WARD STEPHEN G ET AL: "Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents.", CURRENT OPINION IN PHARMACOLOGY. AUG 2003, vol. 3, no. 4, August 2003 (2003-08-01), pages 426 - 434, XP002346297, ISSN: 1471-4892 *

Cited By (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9487772B2 (en) 2000-04-25 2016-11-08 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US8993583B2 (en) 2004-05-13 2015-03-31 Icos Corporation 5-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta
USRE44638E1 (en) 2004-05-13 2013-12-10 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
US9149477B2 (en) 2004-05-13 2015-10-06 Icos Corporation 5-fluoro-3-phenyl-2-[1-(9h-purin-6-ylamino)propyl]-3h-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta
US8779131B2 (en) 2004-05-13 2014-07-15 Icos Corporation 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)-ethyl]-3H-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta
USRE44599E1 (en) 2004-05-13 2013-11-12 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
US8586597B2 (en) 2004-05-13 2013-11-19 Icos Corporation 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta
US8980901B2 (en) 2004-05-13 2015-03-17 Icos Corporation 5-fluoro-3-phenyl-2[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
US9493467B2 (en) 2006-04-04 2016-11-15 The Regents Of The University Of California PI3 kinase antagonists
US8642604B2 (en) 2006-04-04 2014-02-04 The Regents Of The University Of California Substituted pyrazolo[3,2-d]pyrimidines as anti-cancer agents
US9359349B2 (en) 2007-10-04 2016-06-07 Intellikine Llc Substituted quinazolines as kinase inhibitors
US8785456B2 (en) 2008-01-04 2014-07-22 Intellikine Llc Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US9216982B2 (en) 2008-01-04 2015-12-22 Intellikine Llc Certain chemical entities, compositions and methods
US8703777B2 (en) 2008-01-04 2014-04-22 Intellikine Llc Certain chemical entities, compositions and methods
US9655892B2 (en) 2008-01-04 2017-05-23 Intellikine Llc Certain chemical entities, compositions and methods
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
US9637492B2 (en) 2008-03-14 2017-05-02 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US9096611B2 (en) 2008-07-08 2015-08-04 Intellikine Llc Kinase inhibitors and methods of use
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
US9296742B2 (en) 2008-09-26 2016-03-29 Intellikine Llc Heterocyclic kinase inhibitors
US8697709B2 (en) 2008-10-16 2014-04-15 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
US9238070B2 (en) 2008-11-13 2016-01-19 Gilead Calistoga Llc Therapies for hematologic malignancies
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
US10154998B2 (en) 2008-11-13 2018-12-18 Gilead Calistoga Llc Therapies for hematologic malignancies
US8440677B2 (en) 2009-03-24 2013-05-14 Gilead Calistoga Llc Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
US8546409B2 (en) 2009-04-20 2013-10-01 Gilead Calistoga Llc Methods of treatment for solid tumors
US8785454B2 (en) 2009-05-07 2014-07-22 Intellikine Llc Heterocyclic compounds and uses thereof
US9315505B2 (en) 2009-05-07 2016-04-19 Intellikine Llc Heterocyclic compounds and uses thereof
US8569323B2 (en) 2009-07-15 2013-10-29 Intellikine, Llc Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof
US9206182B2 (en) 2009-07-15 2015-12-08 Intellikine Llc Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof
US9522146B2 (en) 2009-07-15 2016-12-20 Intellikine Llc Substituted Isoquinolin-1(2H)-one compounds, compositions, and methods thereof
US8691829B2 (en) 2009-07-21 2014-04-08 Gilead Calistoga Llc Treatment of liver disorders with PI3K inhibitors
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
US8604032B2 (en) 2010-05-21 2013-12-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US9181221B2 (en) 2010-05-21 2015-11-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US9388183B2 (en) 2010-11-10 2016-07-12 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8901133B2 (en) 2010-11-10 2014-12-02 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8809349B2 (en) 2011-01-10 2014-08-19 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US9290497B2 (en) 2011-01-10 2016-03-22 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
US9718815B2 (en) 2011-07-19 2017-08-01 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8785470B2 (en) 2011-08-29 2014-07-22 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9115141B2 (en) 2011-08-29 2015-08-25 Infinity Pharmaceuticals, Inc. Substituted isoquinolinones and methods of treatment thereof
US9546180B2 (en) 2011-08-29 2017-01-17 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9321772B2 (en) 2011-09-02 2016-04-26 The Regents Of The University Of California Substituted pyrazolo[3,4-D]pyrimidines and uses thereof
US9469643B2 (en) 2012-03-05 2016-10-18 Gilead Calistoga, LLC. Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
US8865730B2 (en) 2012-03-05 2014-10-21 Gilead Calistoga Llc Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9255108B2 (en) 2012-04-10 2016-02-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9527847B2 (en) 2012-06-25 2016-12-27 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US10131668B2 (en) 2012-09-26 2018-11-20 The Regents Of The University Of California Substituted imidazo[1,5-a]pYRAZINES for modulation of IRE1
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9359365B2 (en) 2013-10-04 2016-06-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
US10253047B2 (en) 2014-10-03 2019-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same

Also Published As

Publication number Publication date
US20050239809A1 (en) 2005-10-27
CA2552664A1 (fr) 2005-07-28
WO2005067901A2 (fr) 2005-07-28

Similar Documents

Publication Publication Date Title
WO2005067901A3 (fr) Methodes permettant de traiter et de prevenir l'hypertension et les troubles associes a l'hypertension
NL301145I1 (fr)
WO2007126957A3 (fr) Nouveaux composés
WO2008048991A3 (fr) Composés organiques
TN2010000096A1 (en) Oxadiazole - and oxazole - substituted benzimidazole - and indole - derivatives as dgat1 inhibitors
WO2008067121A3 (fr) Méthodes de traitement des troubles cognitifs et de la démence
SI2177224T1 (sl) Spojina za preprečevanje in zdravljenje nepravilnosti, ki vključujejo modulacijo RyR receptorjev
WO2008112659A3 (fr) Régulation de l'ostéopontine
PL1761266T3 (pl) Związki, preparaty i sposoby leczenia lub zapobiegania procesom zapalnym skóry
EP1786515A4 (fr) Traitement du systeme nerveux vegetatif
WO2006113432A3 (fr) Composes, compositions et procedes
WO2003080566A3 (fr) Inhibiteurs d'hydroxylase hif
WO2009089260A3 (fr) Combinaison d'anticorps anti-ctla4 avec des agents de modulation de la tubuline pour le traitement de maladies prolifératives
WO2007076174A3 (fr) Procédés, systèmes et dispositif pour marqueurs multidomaines
WO2009009417A3 (fr) Compositions pharmaceutiques et procédés pour prévenir, traiter ou inhiber des maladies, des troubles ou des affections inflammatoires cutanés et des maladies, des troubles ou des affections associés à un appauvrissement en collagène
WO2007071967A3 (fr) Analgesie
WO2006089009A8 (fr) Procedes et compositions pour le traitement de troubles associes aux lipides
WO2007009044A3 (fr) Traitement de troubles neuronaux
EP1890711A4 (fr) Composés pour le traitement ou la prévention de pathologies ou de troubles liés à l amine oxydase
WO2006050333A3 (fr) Methodes et compositions permettant de moduler l'apoptose
WO2004100873A3 (fr) Composes, compositions et methodes
WO2007038407A3 (fr) Compositions et methodes destinees a traiter des troubles du systeme nerveux
WO2006116184A3 (fr) Methodes et compositions de lutte contre les parasites invertebres
WO2007064997A3 (fr) Composes et procedes permettant d'inhiber l'apoptose
WO2006074443A3 (fr) Compositions d'inhibiteur des pde5 et procedes pour l'immunotherapie

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2552664

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载